Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SYK's flagship Mako Total Knee Platform, its strategic acquisitions and a diversified product portfolio raise optimism about the stock.

Stryker Rallies 19.8% Year to Date: What's Driving the Stock?

Fossil Group

Toyota Motor

Toyota Motor, IBM, Stryker and Fossil Group are included in this Analyst Blog.

The Zacks Analyst Blog Toyota Motor, IBM, Stryker and Fossil Group

Stryker (SYK) is set to acquire Vertos Medical to expand its interventional pain management portfolio.

Stryker's (SYK) Inks Deal to Aid Its Pain Management Portfolio

Portage, Michigan, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire Vertos Medical Inc., a privately held company providing a minimally invasive solution for treating chronic lower back pain caused by lumbar spinal stenosis.

Stryker announces definitive agreement to acquire Vertos Medical, Inc., expanding interventional pain management solutions

Portage, Michigan, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, at the Encore Boston Harbor.

Stryker to participate in the 2024 Wells Fargo Healthcare Conference

Stryker's (SYK) acquisition of care.ai is set to enhance its healthcare IT offerings with AI-assisted virtual care workflows and smart room technology.

Stryker (SYK) to Acquire care.ai to Boost AI-Driven Healthcare

Stryker (SYK) announces the launch of its Pangea Plating System, which is likely to provide solutions for internal fixation and stabilization of bone fractures.

Stryker's (SYK) Pangea System to Enhance Plating Solutions

Portage, Michigan, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable October 31, 2024 to shareholders of record at the close of business on September 30, 2024, representing an increase of 6.7% versus the prior year and unchanged from the previous quarter.

Stryker declares an $0.80 per share quarterly dividend

Medical and surgical products manufacturer Stryker Co. NYSE: SYK is a beneficiary of the acute care boom occurring in the healthcare industry. Acute care is considered short-term intensive hospital-based emergency services that often occur in the emergency department (ED) or intensive care unit (ICU).

Medical Technology Stock Benefits from Rising Acute Care Demand

Stryker (SYK) completes of the acquisition of MOLLI, a privately held company, to strengthen its commitment to advancing surgical solutions in breast cancer care.

Stryker (SYK) Completes MOLLI's Acquisition to Boost Business

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker's new Pangea Plating System enhances trauma care for surgeons with reliable and user-friendly solutions.

Stryker Announces Launch of Pangea Plating System

Stryker is a global medical products and devices company that has global operations in over 75 countries. Historically, the company has been a compounder, generating high returns on capital and has put up impressive top and bottom line growth rates. Recent second quarter results showed strong growth in orthopedics and international markets, with a beat on both revenue and EPS.

Stryker: Wait For A Better Entry Point Post-Q2 Results

While the top- and bottom-line numbers for Stryker (SYK) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Stryker (SYK) Q2 Earnings: A Look at Key Metrics

Stryker (SYK) beats second-quarter earnings estimates, driven by robust sales growth and innovative launches like the LIFEPAK 35 and Spine Guidance 5. The company raises 2024 guidance.

Stryker's (SYK) Q2 Earnings Beat Estimates, Guidance Raised

Here is how Stryker (SYK) and Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Stryker (SYK) This Year?

SAN JOSE, California, USA, July 31, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of MOLLI Surgical Inc., a privately held company specializing in the development of wire-free soft tissue localization technology for breast conserving surgery. MOLLI's portfolio further strengthens Stryker's commitment to advancing surgical solutions in breast cancer care.

Stryker completes acquisition of MOLLI Surgical

Stryker Corporation (NYSE:SYK ) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Kevin Lobo - Chair and Chief Executive Officer Jason Beach - Vice President, Finance and Investor Relations Glenn Boehnlein - Vice President, Chief Financial Officer Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Robert Marcus - JP Morgan Ryan Zimmerman - BTIG Joanne Wuensch - Citibank Travis Steed - Bank of America Matthew O'Brien - Piper Sandler Shagun Singh Chadha - RBC Matthew Miksic - Barclays Steve Lichtman - Oppenheimer Vijay Kumar - Evercore ISI Matthew Taylor - Jefferies Joshua Jennings - TD Cowen Danielle Antalffy - UBS Michael Matson - Needham Caitlin Cronin - Canaccord Jayson Bedford - Raymond James Andrew Ranieri - Morgan Stanley David Roman - Goldman Sachs Operator Welcome to the Second Quarter 2024 Stryker Earnings Call. My name is Luke, and I'm your operator for today's call.

Stryker Corporation (SYK) Q2 2024 Earnings Call Transcript

Stryker Corp posted an upbeat second-quarter profit on Tuesday, as demand for its medical and surgical devices rose, driven by growth in non-urgent surgeries.

Stryker beats Q2 profit estimates on robust demand for medical devices, implants

Stryker (SYK) came out with quarterly earnings of $2.81 per share, beating the Zacks Consensus Estimate of $2.79 per share. This compares to earnings of $2.54 per share a year ago.

Stryker (SYK) Tops Q2 Earnings and Revenue Estimates

Stryker stock fell late Tuesday despite stronger-than-expected second-quarter metrics and hiked sales guidance for the year.

Stryker Stock Falls Despite Second-Quarter Beat, Guidance Hike

Q Guidance System with Spine Guidance 5 Software featuring Copilot is a first-to-market technology, pioneering new planning and surgical capabilities LEESBURG, Va. , July 30, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, today announced that its Q Guidance System with Spine Guidance 5 Software featuring Copilot received 510(k) clearance from the U.S. Food and Drug Administration.

Stryker's Spine Guidance 5 Software featuring Copilot receives 510(k) clearance from FDA

Medtronic

Tempus AI Inc

Across industries, companies will need to adopt AI for growth and survival. A PricewaterhouseCoopers indicates that by 2030, AI could contribute up to $15.7 trillion to the global economy.

3 AI-in-Healthcare Stocks to Buy for Outsized Returns

Evaluate the expected performance of Stryker (SYK) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Seeking Clues to Stryker (SYK) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

Emerson Electric

Intuitive Surgical

NVIDIA

UiPath

Rockwell Automation

Teradyne

Robotics are set to revolutionize industries ranging from transportation to healthcare. And America will be a major growth market.

7 American Robotics Stocks to Buy if You're Betting on Trump 2024

Stryker (SYK) announces the completion of the acquisition of Artelon, a privately held company, to strengthen its foothold in the soft tissue fixation market.

News for Stryker Stock (SYK)